PIK3CA and neoplasm: The high sensitivity, robustness and low cost (less than 1€ per test for reagents) of the multiplex dPCR assays we have developed make them suitable for the qualitative and quantitative clinical detection of PIK3CA mutations in plasma, and we can further speculate that the use of such a sensitive technique should make it possible to avoid reflex testing of the tumor in cases of a negative result on the plasma.